Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Second Primary Malignancy in Multiple Myeloma: a retrospective monocentric analysis of Department of Hematology of the Oncologic Hospital from Cagliari

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAnnamaria LiguoriFPFederica Pilo

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports second primary malignancies in multiple myeloma, highlighting risks in hematologic and solid tumors.

Key Points

  • To describe the occurrence of second primary malignancies (SPMs) in patients with multiple myeloma (MM).
  • Retrospective analysis of symptomatic MM patients diagnosed between 2004 and 2025.
  • Inclusion of patients treated with novel agents, chemotherapy, or both.
  • Follow-up for SPM development using cancer registry data.
  • 42 patients (8.9%) developed at least 1 SPM.
  • 64.3% of SPMs were solid tumors, 35.7% were hematologic malignancies.
  • Median time from MM to SPM diagnosis was 53 months.

Cite This Study

Liguori et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d52bhttps://doi.org/10.1182/blood-2025-7559
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Defining outcomes and risk of second primary malignancy (SPM) in patients with multiple myeloma (MM) in a large, integrated health system.2026
  2. 2Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study2025
  3. 3Investigating additional malignancies rates and overall survival of multiple myeloma patients: a SEER database study2024
  4. 4The risk and survival of multiple myeloma as the second primary malignancy in a single Chinese center2024 · 1 citations
  5. 5Comparative Analysis of Primary and Second Primary Multiple Myeloma: A Propensity Score-Matched Study.2025